Peptide therapy from a compounding pharmacy in 2026: what's available now — and what's coming next

If you've been following peptide therapy, 2026 is the year the ground shifted. In April, the FDA removed twelve peptides from its Category 2 "do not compound" list and scheduled its Pharmacy Compounding Advisory Committee to formally review them — the first real movement toward legitimate pharmacy access in years. Here's what that means in plain language, what you can actually get through a licensed provider today, and what may be coming.

What you can start through Copergrine telehealth today

These are available now through a provider consultation, fulfilled by licensed U.S. compounding pharmacies:

• Sermorelin — a growth-hormone-releasing peptide with a long clinical history, used in medically supervised vitality and recovery protocols. Prescribed after labs and a provider evaluation.
• Glutathione — the body's master antioxidant tripeptide, available as injections commonly used for immune and skin support.
• NAD+ — not technically a peptide, but the most-requested longevity injectable in the same conversation; available in supervised protocols.
• FDA-approved peptide medications — including GLP-1 therapies like semaglutide and tirzepatide for medical weight loss, prescribed as brand products with full lab monitoring.

Every one of these starts the same way at Copergrine: a telehealth visit with a licensed provider, baseline labs where indicated, and a protocol your provider actually monitors — not a checkout cart with a questionnaire.

The twelve peptides the FDA just moved

In April 2026 the FDA removed these from the Category 2 list, and the advisory committee takes them up starting July 23–24, 2026:

BPC-157 · TB-500 · KPV · MOTS-c · Semax · Epitalon · Emideltide (DSIP) — under committee review July 2026.

GHK-Cu · Melanotan II · LL-37 · Dihexa · PEG-MGF — under committee review by early 2027.

Being precise matters here: removal from Category 2 is not the same as approval for compounding. Until the FDA finishes its review and places a substance on the 503A bulk list, licensed pharmacies still cannot legally compound it. Anyone selling you injectable BPC-157 or GHK-Cu today is operating outside that system — usually "research use only" products with no certificate of analysis, no sterility testing, and no pharmacist behind them.

What we recommend while the FDA decides

1. Start with what's legitimate now. Sermorelin, glutathione, NAD+, and supervised GLP-1 therapy cover most of the goals people bring to peptides — recovery, energy, skin, body composition.
2. Get your baseline established. If BPC-157 or GHK-Cu reach the 503A list, patients with an existing provider relationship and recent labs will be first in line.
3. Ask us to flag you. Tell your Copergrine provider which peptides you're watching — when the regulatory status changes, we'll know, and you'll hear it from us before you read it anywhere else.

Book a telehealth peptide consultation, get your labs ordered, and build the protocol that's right for you — from anywhere in Texas.

This article describes the regulatory landscape as of June 2026 and is not medical advice. Peptide therapy availability is determined by your licensed provider and current FDA compounding guidance.